These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1256 related items for PubMed ID: 19951637

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
    Atkins M, Coutinho AD, Nunna S, Gupte-Singh K, Eaddy M.
    J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
    [Abstract] [Full Text] [Related]

  • 24. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
    Crott R, Ali F, Burdette-Radoux S.
    Value Health; 2004 Feb; 7(4):423-32. PubMed ID: 15449634
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
    Elliott TM, Whiteman DC, Olsen CM, Gordon LG.
    Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
    [Abstract] [Full Text] [Related]

  • 27. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
    Reyes C, DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH.
    Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
    [Abstract] [Full Text] [Related]

  • 28. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma.
    Wilson LS, Reyes CM, Lu C, Lu M, Yen C.
    Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
    Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, Aitken JF, Janda M.
    Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
    [Abstract] [Full Text] [Related]

  • 32. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
    Guy GP, Ekwueme DU, Tangka FK, Richardson LC.
    Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
    [Abstract] [Full Text] [Related]

  • 33. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
    Crott R.
    Pharmacoeconomics; 2004 Nov; 22(9):569-80. PubMed ID: 15209526
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of reduced follow-up in malignant melanoma.
    Hengge UR, Wallerand A, Stutzki A, Kockel N.
    J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
    [Abstract] [Full Text] [Related]

  • 35. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.
    Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P.
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):278-84. PubMed ID: 20212521
    [Abstract] [Full Text] [Related]

  • 36. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
    Lyth J, Carstensen J, Synnerstad I, Lindholm C.
    J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
    [Abstract] [Full Text] [Related]

  • 37. Health Outcomes and Direct Healthcare Costs in Patients with Melanoma: Associations with Level of Education.
    Buja A, Rivera M, Zorzi M, Sperotto M, Baracco S, Italiano I, Vecchiato A, Del Fiore P, Avossa F, Corti MC, Guzzinati S, Saia M, Baldo V, Rugge M, Rossi CR.
    Acta Derm Venereol; 2020 Jan 07; 100(1):adv00003. PubMed ID: 31580466
    [No Abstract] [Full Text] [Related]

  • 38. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
    Livingstone E, Krajewski C, Eigentler TK, Windemuth-Kieselbach C, Benson S, Elsenbruch S, Hauschild A, Rompel R, Meiss F, Mauerer A, Kähler KC, Dippel E, Möllenhoff K, Kilian K, Mohr P, Utikal J, Schadendorf D.
    Eur J Cancer; 2015 Mar 07; 51(5):653-67. PubMed ID: 25638778
    [Abstract] [Full Text] [Related]

  • 39. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
    McKendrick J, Gijsen M, Quinn C, Barber B, Zhao Z.
    J Med Econ; 2016 Jun 07; 19(6):587-95. PubMed ID: 26823114
    [Abstract] [Full Text] [Related]

  • 40. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD.
    Appl Health Econ Health Policy; 2009 Jun 07; 7(1):31-41. PubMed ID: 19558193
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 63.